U.S. Markets closed

Dyax chief operating officer leaving in late March

BURLINGTON, Mass. (AP) -- The drugmaker Dyax Corp. said Friday that Chief Operating Officer Ivana Magovcevic-Liebisch will leave the company to join a multinational pharmaceutical company.

Dyax said Magovcevic-Liebisch will leave the company March 29, although she will continue to consult with Dyax. She has worked for the company since April 2001 and was named chief operating officer in August 2012.

Dyax makes Kalbitor, a treatment for acute attacks of hereditary angioedema, a rare genetic disorder that can cause dangerous swelling of the throat or larynx.

Dyax shares were steady at $4.07 per share in midday trading Friday.